These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26400972)

  • 1. Combination drug shows promise for treating agitation in patients with Alzheimer's disease.
    Wise J
    BMJ; 2015 Sep; 351():h5015. PubMed ID: 26400972
    [No Abstract]   [Full Text] [Related]  

  • 2. Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia.
    Ballard C; Sharp S; Corbett A
    JAMA; 2015 Sep 22-29; 314(12):1233-5. PubMed ID: 26393843
    [No Abstract]   [Full Text] [Related]  

  • 3. Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches.
    Corbett A; Ballard C
    Evid Based Med; 2016 Feb; 21(1):25. PubMed ID: 26701197
    [No Abstract]   [Full Text] [Related]  

  • 4. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.
    Newman JC; Steinman MA
    JAMA; 2016 Mar; 315(11):1166. PubMed ID: 26978214
    [No Abstract]   [Full Text] [Related]  

  • 5. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.
    Cummings JL; Siffert J
    JAMA; 2016 Mar; 315(11):1166-7. PubMed ID: 26978215
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.
    Garay RP; Grossberg GT
    Expert Opin Investig Drugs; 2017 Jan; 26(1):121-132. PubMed ID: 27936965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
    Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
    [No Abstract]   [Full Text] [Related]  

  • 12. A naturalistic on-off-on trial of dextromethorphan/quinidine for agitation associated with cerebellar injury.
    Daly JP; Caplan JP
    Psychosomatics; 2012; 53(5):470-3. PubMed ID: 22458990
    [No Abstract]   [Full Text] [Related]  

  • 13. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic management of agitation in Alzheimer's disease.
    Profenno LA; Tariot PN
    Dement Geriatr Cogn Disord; 2004; 17(1-2):65-77. PubMed ID: 14564127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can antidepressant medication relieve agitation in Alzheimer's disease?
    Porsteinsson AP; Smith JS; Keltz MA; Antonsdottir IM
    Expert Rev Neurother; 2014 Sep; 14(9):969-71. PubMed ID: 25148535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agitation in Alzheimer's disease: no to donepezil. Psycho-behavioural measures are better option.
    Prescrire Int; 2008 Oct; 17(97):212. PubMed ID: 19536942
    [No Abstract]   [Full Text] [Related]  

  • 17. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.
    Khoury R; Marx C; Mirgati S; Velury D; Chakkamparambil B; Grossberg GT
    Expert Opin Pharmacother; 2021 May; 22(7):783-795. PubMed ID: 33615952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
    Auchus AP; Bissey-Black C
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):591-3. PubMed ID: 9447502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group.
    O'Gorman C; Khoury R; Anderson A; Carter M; DiCesare F; Dubé S; Ereshefsky L; Grossberg G; Hefting N; Khan S; Lind S; Moebius H; Shiovitz T; Rosenberg P
    J Prev Alzheimers Dis; 2020; 7(4):274-282. PubMed ID: 32920630
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of citalopram in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Keltz MA; Smith JS
    Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.